In the News

IPA News

March 7th, 2024

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, BRITISH COLUMBIA (CANADA), March 7, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.)...

November 27th, 2023

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

VICTORIA, British Columbia, November 27, 2023 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director...

June 13th, 2023

IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

VICTORIA, British Columbia, June 13, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration...

IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

VICTORIA, British Columbia, June 6, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and...

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has...

Connect with IPA

Contact Us